Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sichuan Huiyu Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:688553'
s EV-to-FCF Range Over the Past 10 Years
Min: -616.9 Med: -9.41 Max: 1661.3
Current: 159.97
During the past 9 years, the highest EV-to-FCF of Sichuan Huiyu Pharmaceutical Co was 1661.30. The lowest was -616.90. And the median was -9.41.
SHSE:688553's EV-to-FCF is ranked worse than 91.21% of 569
companies
in the Drug Manufacturers industry
Industry Median: 20.47
vs SHSE:688553: 159.97
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sichuan Huiyu Pharmaceutical Co (SHSE:688553) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sichuan Huiyu Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Sichuan Huiyu Pharmaceutical Co's share price for today is ¥10.27.
Sichuan Huiyu Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.034.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sichuan Huiyu Pharmaceutical Co EV-to-FCF Related Terms
Sichuan Huiyu Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Huiyu Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Huiyu Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sichuan Huiyu Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sichuan Huiyu Pharmaceutical Co's EV-to-FCF falls into.
Sichuan Huiyu Pharmaceutical Co's current Enterprise Value is ¥4,477 Mil.
Sichuan Huiyu Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Huiyu Pharmaceutical Co (SHSE:688553) has a EV-to-FCF of 159.97 as of Jul. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sichuan Huiyu Pharmaceutical Co and its competitors. According to the industry distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #519 out of 569 companies in the Drug Manufacturers industry, placing it in the top 91.2%.
Is Sichuan Huiyu Pharmaceutical Co's EV-to-FCF too high?
Sichuan Huiyu Pharmaceutical Co's current EV-to-FCF is 159.97. The Drug Manufacturers industry median EV-to-FCF is 20.47. Sichuan Huiyu Pharmaceutical Co's value of 159.97 is 681.5% above this industry median. Based on the distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #519 out of 569 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sichuan Huiyu Pharmaceutical Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Huiyu Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #519 out of 569 companies for EV-to-FCF. This places Sichuan Huiyu Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 20.47. Sichuan Huiyu Pharmaceutical Co's value of 159.97 is 681.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.47, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Huiyu Pharmaceutical Co's current EV-to-FCF of 159.97 is 681.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sichuan Huiyu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Huiyu Pharmaceutical Co's current EV-to-FCF is 159.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Huiyu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Huiyu Pharmaceutical Co (SHSE:688553) is currently considered Fairly Valued. The stock's GF Value™ is ¥9.85, compared to a current price of ¥10.27 — trading 4.3% above its estimated fair value. The current EV-to-FCF is 159.97 and 681.5% above the Drug Manufacturers industry median of 20.47. Sichuan Huiyu Pharmaceutical Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sichuan Huiyu Pharmaceutical Co (SHSE:688553), the current EV-to-FCF is 159.97 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Huiyu Pharmaceutical Co (SHSE:688553) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Huiyu Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥10.27 is trading 4.3% above its estimated GF Value™ of ¥9.85.
GuruFocus considers Sichuan Huiyu Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:688553:
EV-to-FCF: 159.97
GF Value™: ¥9.85 vs. price of ¥10.27 (4.3% above fair value)
Industry Position: 681.5% above the Drug Manufacturers median (#519 of 569)
No single metric tells the full story. See the SHSE:688553 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Huiyu Pharmaceutical Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688553 has been successfully added to your 
